- Home
- ANVS vs ASRT Comparison
ANVS vs ASRT Comparison
Compare ANVS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ASRT
- Stock Information
- Founded
- ANVS 2008
- ASRT 1995
- Country
- ANVS United States
- ASRT United States
- Employees
- ANVS N/A
- ASRT N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- ASRT Health Care
- Exchange
- ANVS Nasdaq
- ASRT Nasdaq
- Market Cap
- ANVS 92.6M
- ASRT 85.1M
- IPO Year
- ANVS 2020
- ASRT 1997
- Fundamental
- Price
- ANVS $3.08
- ASRT $0.81
- Analyst Decision
- ANVS Strong Buy
- ASRT Strong Buy
- Analyst Count
- ANVS 6
- ASRT 4
- Target Price
- ANVS $29.67
- ASRT $3.19
- AVG Volume (30 Days)
- ANVS 499.1K
- ASRT 361.1K
- Earning Date
- ANVS 03-31-2025
- ASRT 03-10-2025
- Dividend Yield
- ANVS N/A
- ASRT N/A
- EPS Growth
- ANVS N/A
- ASRT N/A
- EPS
- ANVS N/A
- ASRT N/A
- Revenue
- ANVS N/A
- ASRT $125,763,000.00
- Revenue This Year
- ANVS N/A
- ASRT N/A
- Revenue Next Year
- ANVS N/A
- ASRT $1.84
- P/E Ratio
- ANVS N/A
- ASRT N/A
- Revenue Growth
- ANVS N/A
- ASRT N/A
- 52 Week Low
- ANVS $2.99
- ASRT $0.73
- 52 Week High
- ANVS $20.00
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ANVS 20.82
- ASRT 43.92
- Support Level
- ANVS $2.99
- ASRT $0.78
- Resistance Level
- ANVS $5.50
- ASRT $0.83
- Average True Range (ATR)
- ANVS 0.34
- ASRT 0.03
- MACD
- ANVS -0.18
- ASRT 0.00
- Stochastic Oscillator
- ANVS 3.59
- ASRT 39.86
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.